Skip to main content
Premium Trial:

Request an Annual Quote

Diagenode Acquires Epigenetics Firm Nxt-Dx

NEW YORK (GenomeWeb) — Diagenode announced on Thursday that it has acquired Belgian epigenetics service provider Nxt-Dx.

Terms of the deal were not disclosed.

According the Diagenode, Nxt-Dx's offerings include targeted DNA methylation assays, as well as chromatin and mRNA wet lab and analysis services. Diagenode expects the transaction to bolster its suite of epigenomics service platform and enhance its epigenetic biomarker discovery efforts.

"The services offered by Nxt-Dx perfectly complement Diagenode's current chromatin, RNA, and DNA methylation assay services and will allow researchers to focus both on discovery and validation of epigenetic signatures," Diagenode CEO Didier Allaer said in a statement. "Additionally, the targeted DNA methylation analyses that Nxt-Dx offers now close the gap between epigenetics and IVD assay development."

Diagenode — which is based in Liège, Belgium and maintains a US subsidiary in New Jersey — has been developing a clinical breast cancer test using a novel DNA methylation–based immune response signature in collaboration with researchers from the Université Libre de Bruxelles Cancer Research Center.